SecBot SecBot

MGRX

MANGOCEUTICALS, INC.
Nasdaq· Services-Misc Health & Allied Services, NEC· Inc. TX· CIK 0001938046 Healthcare & Medical Devices
$0.2440 +0.01 (+5.17%)
Oct 26 4:00 PM ET · prev $0.2320
Market cap
$5.4M
Nano cap
Next earnings
Nov 12
in 16 days
1 year
−88.6%
from $2.14 · Oct 27
30 days
−36.6%
from $0.3850
52-week range
$0.1620–2.21
−89% from high · low Mar 20
Avg volume 20D
616.0K
Oct 1 spike 2.13M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q1 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 2 bearish · 3 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/6 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH Mangoceuticals is conducting a dilutive registered direct offering of 657,000 shares of common stock and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q1 2026: 2 added (0 new), 0 trimmed or exited.

  • TrendDOWNTREND

    39% below its 50-day average.

Who's buying

13F· Q1 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCADD194,482$70.0K
JANE STREET GROUP, LLCADD72,746$26.2K
VANGUARD GROUP INCDOUBLED489,532$362.3K
UBS Group AGDOUBLED46,167$34.2K
NORTHERN TRUST CORPADD37,579$27.8K
BANK OF AMERICA CORP /DE/TRIM107$79.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED87,974$192.7K
UBS Group AGNEAR_EXIT3$7.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
MGRX Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 1, 2026
Press release
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No…
Aug 28, 2026
Reg SHO list
Reg SHO Threshold: MGRX exited the threshold list
MANGOCEUTICALS INC COM NEW (TX | On list since 2026-08-12
Aug 12, 2026
Reg SHO list
Reg SHO Threshold: MGRX entered the threshold list
MANGOCEUTICALS INC COM NEW (TX | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding
Aug 12, 2026
Earnings date
MGRX Q2 2026 Earnings Scheduled — 2026-08-12
Aug 4, 2026
Press release
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has…

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 11, 2026
Cohen Jacob D.
Chief Executive Officer
GIFT2,000,000 sh
Jul 28, 2026
Cohen Jacob D.
Chief Executive Officer
AWARD2,000,000 sh
Jul 28, 2026
JOHNSTON EUGENE M
CFO
AWARD100,000 sh
Jul 28, 2026
Hamilton Alex P.
Director
AWARD100,000 sh
Mar 16, 2026
Cohen Jacob D.
Chief Executive Officer
AWARD50,000 sh
Mar 16, 2026
Cohen Jacob D.
Chief Executive Officer
AWARD83,333 sh
Mar 16, 2026
Cohen Jacob D.
Chief Executive Officer
TO ISSUER50,000 sh
Mar 16, 2026
Cohen Jacob D.
Chief Executive Officer
TO ISSUER83,333 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 31, 2026Volatility PauseResumed
Jul 31, 2026Volatility PauseResumed
Jul 31, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 SEC
Mangoceuticals closed a ~$493K registered direct offering at $0.75/unit (74% premium to the $0.43 recent close)…
8-K — Impact 5/10
Oct 9, 2026 SEC
Mangoceuticals is conducting a dilutive registered direct offering of 657,000 shares of common stock and 657,000…
424B5 — Impact 6/10
Oct 6, 2026 SEC
Jacob D. Cohen and The Tiger Cub Trust filed Amendment No. 6 to their Schedule 13D, reporting a combined beneficial…
SC 13D/A — Impact 5/10
Oct 1, 2026 Other
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral
Aug 11, 2026 Insider
Cohen Jacob D. gifted 2,000,000 shares
Chief Executive Officer
Jul 28, 2026 Insider
Cohen Jacob D. was granted 2,000,000 shares
Chief Executive Officer
Jul 28, 2026 Insider
JOHNSTON EUGENE M was granted 100,000 shares
CFO
Mar 31, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
194,482 shares ($70.0K)

SecBot reports

6 filings · 1 press release · 3 bullish · 2 bearish · 1 neutral
All MGRX filing & press-release reports (7)